I期临床-话题@MedSci

#I期临床#

570篇内容 | 7037人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652914, encodeId=de5a165291449, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=59, createdTime=2019-10-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652838, encodeId=d79d1652838e9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=52, createdTime=2019-01-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652874, encodeId=ccc816528e4b1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=89, createdTime=2020-01-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652897, encodeId=949f165289e61, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, objectType=article, longId=166545, objectId=dc1716654548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc1716654548, replyNumber=0, likeNumber=64, createdTime=2019-07-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc1716654548, moduleTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc1716654548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652918, encodeId=2ed516529189d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿尔茨海默症治疗药物的研发仍在前赴后继：Tau抑制剂ACI-3024的I期临床正式开始, objectType=article, longId=175767, objectId=e79f1e57677e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e79f1e57677e, replyNumber=0, likeNumber=87, createdTime=2019-09-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e79f1e57677e, moduleTitle=阿尔茨海默症治疗药物的研发仍在前赴后继：Tau抑制剂ACI-3024的I期临床正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e79f1e57677e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652906, encodeId=23341652906ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, objectType=article, longId=172193, objectId=f8e41e2193df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e41e2193df, replyNumber=0, likeNumber=45, createdTime=2019-09-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e41e2193df, moduleTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e41e2193df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652882, encodeId=0e02165288270, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=96, createdTime=2020-02-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652872, encodeId=42e016528e2d8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展, objectType=article, longId=161017, objectId=3f0216101ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0216101ea6, replyNumber=0, likeNumber=78, createdTime=2019-05-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0216101ea6, moduleTitle=PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0216101ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652873, encodeId=6a4c16528e3fa, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=78, createdTime=2019-06-23, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652896, encodeId=8a11165289673, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=罗沙司他全球III期临床研究证实其心血管安全性, objectType=article, longId=166305, objectId=121416630562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121416630562, replyNumber=0, likeNumber=77, createdTime=2019-11-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121416630562, moduleTitle=罗沙司他全球III期临床研究证实其心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121416630562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652888, encodeId=a6011652888b6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=51, createdTime=2019-12-29, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652856, encodeId=9af21652856a6, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》, objectType=article, longId=159598, objectId=808b1595986f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=808b1595986f, replyNumber=0, likeNumber=23, createdTime=2019-05-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=808b1595986f, moduleTitle=【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=808b1595986f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652864, encodeId=777e165286486, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, objectType=article, longId=160427, objectId=61c716042e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c716042e5f, replyNumber=0, likeNumber=65, createdTime=2019-09-24, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c716042e5f, moduleTitle=II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61c716042e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652843, encodeId=3a9c16528430a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=62, createdTime=2019-06-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652871, encodeId=1ff916528e1bd, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, objectType=article, longId=160662, objectId=4eb716066282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb716066282, replyNumber=0, likeNumber=51, createdTime=2019-03-21, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb716066282, moduleTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb716066282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652840, encodeId=9226165284052, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, objectType=article, longId=153201, objectId=ee2f15320164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee2f15320164, replyNumber=0, likeNumber=0, createdTime=2019-03-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee2f15320164, moduleTitle=JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee2f15320164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652878, encodeId=7e8d16528e814, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=基石药业HDAC6抑制剂CS3003在中国I期临床试验获批, objectType=article, longId=162295, objectId=862416229577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=862416229577, replyNumber=0, likeNumber=86, createdTime=2020-02-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=862416229577, moduleTitle=基石药业HDAC6抑制剂CS3003在中国I期临床试验获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=862416229577)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652877, encodeId=954c16528e7db, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, objectType=article, longId=161551, objectId=9ed316155121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed316155121, replyNumber=0, likeNumber=66, createdTime=2019-06-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed316155121, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed316155121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652830, encodeId=4407165283085, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著, objectType=article, longId=145489, objectId=b5d414548996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5d414548996, replyNumber=0, likeNumber=0, createdTime=2019-05-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5d414548996, moduleTitle=Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5d414548996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652876, encodeId=fdd116528e68b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, objectType=article, longId=161507, objectId=c9f516150e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f516150e26, replyNumber=0, likeNumber=85, createdTime=2019-12-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f516150e26, moduleTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f516150e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-10-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2019-01-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2020-01-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据

2019-07-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿尔茨海默症治疗药物的研发仍在前赴后继：Tau抑制剂ACI-3024的I期临床正式开始

2019-09-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

2019-09-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2020-02-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

PTR-01（BBP-589）治疗隐性营养不良性大疱性表皮松解症的I/II期临床正式开展

2019-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-06-23

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

罗沙司他全球III期临床研究证实其心血管安全性

2019-11-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-12-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

【开年大吉】张力教授领衔在《柳叶刀》杂志发表《中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告》

2019-05-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

II期临床研究FUZE评估Debio 1347治疗晚期实体瘤的疗效

2019-09-24

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ALK阳性肺癌全新III期临床研究成果

2019-06-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据

2019-03-21

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床

2019-03-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

基石药业HDAC6抑制剂CS3003在中国I期临床试验获批

2020-02-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果

2019-06-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Gastroenterology：GS-0976治疗非酒精性脂肪性肝炎II期临床效果显著

2019-05-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败

2019-12-14

科室
- - 订阅+
  - 更多科室
工具
服务